



MANHATTAN SCIENTIFICS, INC.

The Chrysler Bldg., 32nd Floor
405 Lexington Ave.,
New York, N.Y. 10174
917.919.0370
www.mhtx.com


Investment Profile

OTC BB: MHTX

IR Contact: Frank N. Hawkins, Jr.
Hawk Associates
305.451.1888

August 17, 2010

MHTX Promoting a New Technology to Eliminate False Positive Cancer Analysis. Acquires Exclusive Rights to Nanomedicine Technology for Early Cancer Detection and Treatment.



Highlights

07/26/10

MHTX promoting a new technology to eliminate false positive cancer analysis. New technology holds promise for zero-error cancer pathology.

4/21/2010

MHTX early cancer detection technology able to detect breast cancer three years earlier than standard mammogram.

02/25/10

Manhattan Scientifics acquires exclusive rights to nanomedicine technology for early cancer detection and treatment

09/21/2009

Carpenter Technology to develop, market high-strength metals in licensing agreement with MHTX.

2/11/2009

Manhattan Scientifics Completes \$1.0 Million Equity Raise.

12/9/2008

FDA Approval Granted On New Titanium Dental Implant; Double-strength Metal Expected to Integrate Into Bone Up To 20

Company Description

Manhattan Scientifics Inc. develops and nurtures financially promising technology companies with global application potential. The company and its affiliates now own a significant IP portfolio and patents in high-strength metals, early cancer detection, alternative energy, hydrogen fuel cells and computer 3D touch haptics.

The company's business model is to commercialize, bringing products to market to create profit for its shareholders through partnerships with manufacturers and licensees of its patents.

Manhattan Scientifics has enjoyed a special informal relationship and a successful history in tech-transfer from the Los Alamos National Laboratory (LANL) and the Sandia National Laboratory (SNL).

An example of this relationship was the seed funding and launch of Novint Technologies, which acquired the exclusive, perpetual, global license to the Haptics technology from Sandia National Labs and now trades as a listed company in the OTC BB under ticker symbol NVNT. For more information, visit <http://www.novint.com>.

OTC BB: MHTX

Closing Price (08/16/10)	\$0.06
Market Cap.	\$25.29 mil.
52-Week Range	\$0.04 - \$0.11
Avg, Daily Volume (3 mo.)	401,498
Basic Shares	396 mil.
Est. Public Float	126 mil.
Insider Ownership	33%
Fiscal Year End	Dec. 31

Projects

Nanomedicine - Manhattan Scientifics is collaborating with Dr. Edward Flynn, owner of Senior Scientific, to commercialize a nanomedicine technology - specifically a biomagnetic detection of cancer and other diseases through magnetic field sensors that make it possible to identify and image small clusters of cancer cells increasing the possibility of finding cancer at a much earlier stage than is currently possible.

NanoTitanium - Manhattan Scientifics owns



CHRYSLER BUILDING | 405 LEXINGTON AVE, 26TH FLR | NY NY | 10174 | 212.541.2465

227 ATLANTIC BOULEVARD | KEY LARGO | FLORIDA | 33037 | TEL: 305.451.1888

Investment Profile

MHTX



MANHATTAN SCIENTIFICS, INC.

exclusive rights to the key patents and IP portfolio to produce and market NanoTitanium and other ultra fine grain nano-structured metals. The company has acquired Metallicum along with its patented rights for new ultra fine grain metals that may advance the transportation and medical device industry, emphasizing dental implants, cardiovascular stents and a wide range of prosthetic applications including artificial knees, shoulders, and hips.

NanoTitanium is highly compatible with bone and is thought to provide stronger, faster bonding with improved strength, biocompatibility, longer life and improved wear and tear.

In terms of transportation, NanoTitanium may profoundly impact today's fuel economy. This technology is expected to trim thousands of pounds from airplanes and hundreds of pounds from cars without sacrificing structural strength or adding significant cost.

Alternative Energy Technologies -

Manhattan Scientifics is pursuing several potential MHTX owns the patents and IP technology for the award winning NovArs hydrogen powered fuel cell engine. Light weight and portable, it may be ideal to provide an inexpensive and environmentally friendly "green" system to drive scooters, bicycles, power tools, portable electronics, wheel chairs, golf carts and home emergency power.

Haptics - Manhattan Scientifics provided \$4.5 million seed funding to launch Novint Technologies Inc. The patented Novint Falcon, a computer game controller, enables the ability to touch and realistically feel images on a computer screen including texture, weight, motion and viscosity. The company is gaining recognition and growing rapidly, recently signing an agreement with Electronic Arts, whereby the company will create games compatible with the controller.

Technology and Background

Manhattan Scientifics began as a technology incubator. The company has focused on acquiring several technologies in the fields of holographic data storage, water purification, alternative energy, advanced computer haptics and, most recently,

nanotechnology. The majority of MHTX's commercial technologies come from U.S. government laboratories in New Mexico.

The Outlook

MHTX continues its role as pioneer in the fields of nano technology, alternative energy and advanced computing.

Carpenter Technology Corp. (CRS) will develop and market a new new class of high-strength metals under exclusive license to MHTX and Los Alamos National Labs. The contract includes minimum annual payments over a four year period with royalty payments as a percent of gross sales. The ultra fine grain metals have broad applications in medicine and industry. The agreement is providing positive cash flow and profitability to MHTX.

MHTX has acquired full commercial rights to the body of work of nuclear physicist Edward R. Flynn, Ph.D. and his company Senior Scientific LLC. His breakthrough technology focuses on the emerging field of nanomedicine, with emphasis on the early detection and localization of cancer and other diseases, providing image-guided therapy for treatment.

Early detection of cancer can be critical to effective treatment. Current mammography cannot detect a breast cancer tumor until it has grown to over ten million cells. Dr. Flynn's technology has proven the ability to detect breast cancer tumors while they are only 1% that large, resulting in an hundred-fold increase in sensitivity and early detection.

When fully developed and commercialized, Dr. Flynn's biomagnetic -based system will be 100% radiation free, unlike current radiation-based mammogram tests. His approach uses sophisticated magnetic field sensors to measure extremely small magnetic fields emitted by magnetic nanoparticles that have been injected into the body and targeted specifically toward cancer cells. The method yields high contrast images of tumors compared to normal cells. This makes it possible to identify and image tiny clusters of cancer cells providing the ability to find cancer at substantially earlier stages

than is presently possible.

To reduce harm from over-treatment and radiation, new medical guidelines recently issued by the U.S. Preventative Services Task Force recommended that women begin regular breast cancer screening at age 50, rather than at age 40. "Annual mammograms for most women in their 40's have more drawbacks than benefits." a report said.

The company also has a joint project with Carpenter and Cochlear to create customized metals that integrate with human tissue to produce longer lasting prosthetics

Management Team

Chairman and CEO - **Emmanuel (Manny) Tsoupanarias**
Non-executive Chairman - **Marvin Maslow**
Special Counsel - **Larry Schatz, Esq.**
Director - **Leonard Friedman, Esq.**
Director - **Frank Georgiou**
Director - **Chris Theoharis**

Scientific Advisory Board

Dr. Terry Lowe
Co-inventor of the nano-structured metals process, president and chief scientist for the Metallicum unit of MHTX

Risk Factors

Access to sufficient capital to bring product to market; to defend its patents; to surpass its competitors.. Ability to recruit additional senior management.
Potential technical obsolescence.
Numerous well-capitalized competitors.